<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01861990</url>
  </required_header>
  <id_info>
    <org_study_id>VA2013</org_study_id>
    <secondary_id>IRG-97-219-14</secondary_id>
    <nct_id>NCT01861990</nct_id>
  </id_info>
  <brief_title>Valproic Acid in Childhood Progressive Brain Tumors</brief_title>
  <official_title>Valproic Acid for Children With Recurrent and Progressive Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigates valproic acid added to radiation and temozolomide therapy (standard of
      care) for progressive or recurrent pediatric brain tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with progressive or recurrent pediatric brain tumors are administered valproic acid,
      an HDAC inhibitor, along with standard of care therapy (radiation and temozolomide) for
      induction therapy. Thereafter, patients will be able to continue on valproic acid and
      temozolomide therapy as long as the combination is well tolerated and the tumor is not
      progressing.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Feasibility of the trial was proven to be absent.
  </why_stopped>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Completion of protocol</measure>
    <time_frame>2 months</time_frame>
    <description>Number of participants completing the protocol will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>2 months</time_frame>
    <description>Participants will be evaluated for progression every 2 months while on the study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pediatric Brain Tumor</condition>
  <condition>Glioma</condition>
  <condition>Anaplastic Astrocytoma</condition>
  <condition>Medulloblastoma</condition>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will be enrolled on to one, open-label arm. Participants will be treated with valproic acid in addition to standard of care therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproic Acid</intervention_name>
    <description>All participants enrolled on valproic acid arm.</description>
    <arm_group_label>Treatment arm</arm_group_label>
    <other_name>Valproate, VPA, Depakote, Depakote ER, Depakene</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject, parent, or guardian willing and able to give informed consent

          -  Recurrent or progressive pediatric brain tumor, with MRI evidence of disease

          -  Age at first diagnosis of brain tumor 1-21 years old

          -  Lansky or Karnofsky performance score of at least 50 at diagnosis

        Exclusion Criteria:

          -  Pregnancy

          -  Prior intolerance to valproic acid

          -  History of use of temozolomide

          -  Use of enzyme inducing anticonvulsant medications (see appendix B)

          -  Known urea cycle disorder (e.g. ornithine transcarbamylase deficiency)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy L Bredlau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Van Nifterik KA, Van den Berg J, Slotman BJ, Lafleur MV, Sminia P, Stalpers LJ. Valproic acid sensitizes human glioma cells for temozolomide and Î³-radiation. J Neurooncol. 2012 Mar;107(1):61-7. doi: 10.1007/s11060-011-0725-z. Epub 2011 Oct 26.</citation>
    <PMID>22037799</PMID>
  </reference>
  <reference>
    <citation>Asklund T, Kvarnbrink S, Holmlund C, Wibom C, Bergenheim T, Henriksson R, Hedman H. Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors. Anticancer Res. 2012 Jul;32(7):2407-13.</citation>
    <PMID>22753697</PMID>
  </reference>
  <reference>
    <citation>Fu J, Shao CJ, Chen FR, Ng HK, Chen ZP. Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neuro Oncol. 2010 Apr;12(4):328-40. doi: 10.1093/neuonc/nop005. Epub 2009 Oct 15.</citation>
    <PMID>20308311</PMID>
  </reference>
  <reference>
    <citation>Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, Rossetti AO, Lacombe D, Mirimanoff RO, Vecht CJ, Stupp R. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology. 2011 Sep 20;77(12):1156-64. doi: 10.1212/WNL.0b013e31822f02e1. Epub 2011 Aug 31.</citation>
    <PMID>21880994</PMID>
  </reference>
  <reference>
    <citation>Masoudi A, Elopre M, Amini E, Nagel ME, Ater JL, Gopalakrishnan V, Wolff JE. Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res. 2008 Jul-Aug;28(4C):2437-42.</citation>
    <PMID>18751431</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2013</study_first_submitted>
  <study_first_submitted_qc>May 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2013</study_first_posted>
  <last_update_submitted>May 21, 2015</last_update_submitted>
  <last_update_submitted_qc>May 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Amy-Lee Bredlau</investigator_full_name>
    <investigator_title>Director, Pediatric Brain Tumor Program</investigator_title>
  </responsible_party>
  <keyword>Glioma</keyword>
  <keyword>Glioblastoma</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Child</keyword>
  <keyword>Brain tumor</keyword>
  <keyword>Astrocytoma</keyword>
  <keyword>Medulloblastoma</keyword>
  <keyword>PNET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

